[Global Times reporter & nbsp; “War” broke out between the European Union and the UK over the supply of new crown vaccines, the Guardian reported on the 26th. The European Union threatened to intensify the review and delay or even interrupt the supply of vaccines produced in EU countries to the UK due to dissatisfaction with AstraZeneca, a British pharmaceutical company, suddenly breaking its promise and planning to sharply reduce the supply of vaccines. At the same time, German media also revealed that the actual effectiveness of AstraZeneca vaccine for the elderly is “extremely low”, even less than 10%. AstraZeneca is “very angry” about this.
The European Union is extremely dissatisfied with the “unreasonable” reduction of vaccine supply by us and British pharmaceutical giants against the background of the continuous spread of the epidemic, AFP said on the 26th. With vaccine supply as the fuse, the already serious gap between the EU and the UK has been further widened. The guardian said that the European Union “threatened to suspend the supply of vaccines to the UK” because of dissatisfaction with AstraZeneca’s “discount” on vaccine supply. The head of the EU health department decided to require pharmaceutical companies to declare in advance when exporting vaccines to countries outside the EU, otherwise they would not be approved. This means that Pfizer, an American company that produces vaccines in Belgian factories and then ships them to the UK, must seek permission from the European Union in advance. Britain, which has ordered Pfizer’s vaccine, will face the risk of a “cut-off”. The UK has ordered at least 40 million doses of the vaccine from Pfizer.
For the United Kingdom, which is deeply in the plight of the epidemic, the delay in the supply of vaccines is unbearable. Last August, the European Union ordered at least 300 million doses of the vaccine from AstraZeneca and paid 340 million euros (about 2.67 billion yuan), which promised to supply about 80 million doses of the vaccine by the end of March this year. But on Friday, AstraZeneca suddenly said it could only supply 31 million doses of vaccine to the European Union by the end of March due to insufficient capacity in a vaccine factory, 60% less than the promised delivery.
The Daily Mail said the move “infuriated the European Union.”. On the 25th local time, European Commission President Frederick von der lain and AstraZeneca president Pascal soboko had a “heated” talk about the supply of new crown vaccine. A spokesman for the former said the president of the European Commission “solemnly reminded” the other party that the European Union had already paid a large amount of money in advance to support the company’s capacity expansion. The latter said that the company is “making every effort to ensure the provision of vaccines to millions of European people.”.
Focusing on the supply of vaccines, European Commission health and food safety commissioner kyria gides said in a statement on the 25th that AstraZeneca’s plan to reduce vaccine deliveries in the next few weeks is “unacceptable,” AFP said. The European Commission will set up a transparent mechanism for vaccine export to strengthen the review of vaccine export. Kiriakidis said AstraZeneca’s explanation for reducing vaccine supply “lacks sufficient detail” and is unconvincing. She wrote to the company at the end of last week, stressing the importance of complying with the agreed delivery schedule and asking for information on where the company has produced the vaccines so far, whether they have been delivered and where they are going. Health officials from the European Commission and Member States also held video conferences with representatives of the company. Kiriakidis said that the European Commission has proposed to “establish an export transparency mechanism as soon as possible”, which requires any vaccine exported from EU countries to obtain EU approval.
British public opinion believes that this is the EU’s “revenge” on the UK in terms of vaccine supply. In addition to being tough on vaccine supply, some EU experts also openly questioned the effectiveness of the UK vaccine, the Daily Mail said. German Bild and Bild recently quoted German government officials as saying that EU experts revealed to them that according to unpublished clinical reports, the actual effectiveness of Oxford AstraZeneca vaccine in the UK for people over 65 years old is only 8%. In response, a spokesman for AstraZeneca retorted that the statement that the effective rate of the company’s vaccine was less than 10% was “100% false”. The Joint Commission on vaccination and immunization (JCVI) in the UK supports mass use of the vaccine. According to the company’s paper published in the international authoritative medical journal the lancet in November last year, “all elderly people have antibodies in their bodies after the second vaccination.”.
The European Union and its member states are quite dissatisfied with the continuous postponement of supply plans by us and British pharmaceutical companies, and intend to set up a transparent mechanism for vaccine export as an important way to restrict vaccine suppliers, AFP said. European Council President Michelle said on the 24th that the European Union would urge pharmaceutical companies to abide by the previously signed contracts, and said that “all means will be taken” to ensure timely supply of vaccines when necessary. Jens Spang, the German health minister, said the EU needs to step up its review to find out which vaccines are being exported. Only in this way can it understand whether the contracts with suppliers are implemented fairly. It is “reasonable requirement” to obtain EU approval before vaccine export.
The guardian said that with the development and production of vaccines, European countries have started vaccination programs one after another, but the progress of vaccination varies greatly among EU countries, and the overall progress lags behind that of the United States and the United States. Data show that only about 8.5 million people in EU member states have received at least one dose of vaccine, with an average of 1.89 doses per 100 people. In the UK, 10.38 doses were given to every 100 people, compared with 6.6 doses in the United States. Differences in vaccination further exacerbate the transatlantic conflict. Although Europe and the United States have carried out cooperation in vaccine research and development, the competition and contradiction between countries are very sharp in terms of vaccine supply related to epidemic prevention.